Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06284629

Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.

The overall aim of the trial is to compare the efficacy of using wearables and patient-reported outcome measures versus standard care in enhancing the timeliness of referrals to advanced monitoring of treatments for people with Parkinson's Disease.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rigshospitalet Glostrup, Glostrup Municipality, Denmark

Loading trial locations.

About this study

The study is a multicentre, parallel group, randomized controlled trial, investigating the value of using wearable devices and electronic patient-reported outcome measurements to improve clinical decision-making related to people with Parkinson's Disease.

Data from a wearable device and a mobile app will be compared to current standard of care.

90 participants will be recruited from the uptake area of the Movement Disorder Clinics (MDC) at Rigshospitalet Glostrup (RHG) and Odense University Hospital (OUH), as well as from 5 private practice neurologists in Denmark. They will equally be randomized to one of two groups: Intervention or Standard of Care.

Each participant will take part of the trial for one year, in which they will have 5 study visits:

  • Baseline
  • Clinical visits every 3 months (months 3, 6 and 9)
  • Final visit after 12 months

They will be asked to wear the device and report symptoms in the app for one year. We will then compare decisions made related to changes in medication and referrals to advanced treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with Idiopathic Parkinson's Disease
  • Taking five or more doses of levodopa daily
  • Experiencing fluctuations in motor function with regards to OFF time and/or dyskinesia.
  • Able to utilize a digital product, either alone or assisted by a caregiver.

Exclusion criteria

  • Consistent use of a wheelchair or walker which may interfere significantly with the remote monitoring of PD motor symptoms.
  • Lack of understanding and proficiency in the Danish language.
  • Inability to use wearable devices due to non-compliance, physical and/or skin sensitivity.
  • Suffering from severe psychiatric disorders.
  • Otherwise not qualified to receive advanced treatment (e.g., advanced cancer, severe heart failure).
  • Already undergoing advanced treatment.
  • Diagnosed with atypical or secondary parkinsonism.
  • Other patient groups otherwise deemed ineligible by the project manager.

Treatment and study plan

Neptune

Device

Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.

Other names: Neptune Care

Standard clinical care

Other

Treatment and management according to standard clinical care

Primary outcomes

  1. Differences between groups in algorithm-based motor symptom burden (time spent in the ON state without dyskinesias) at referral to evaluation for advanced treatment.

    Time frame: 1 year

    Time spent in the ON state without dyskinesias, as measured by the Neptune algorithm

Secondary outcomes

  1. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    Global Sleep Assessment Scale (GSAQ). Every question is scored from 0-3 (highest worst)

  2. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    Non-Motor Symptom Scale (NMSS). Scored from 0-360 (highest worst)

  3. Changes in type of, frequency and dose of medication (calculated Levodopa Equivalent Dose, LED, by use of Tomlinson's scale)

    Time frame: 1 year

    Levodopa Equivalent Dose, LED, by use of Tomlinson's scale.

  4. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scored from 0-52 (UPDRS-II), 0-132 (UPDRS-III) and 0-44 (UPDRS-IV) (highest worst)

  5. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    Parkinson's Disease Questionnaire (PDQ-39). Scored from 0-100 (highest worst)

  6. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    EuroQol Questionnaire (EQ5D-5L). Scored from 0-1 and 0-100 (highest best).

  7. Differences in questionnaire data from baseline (inclusion visit) to end-of-intervention.

    Time frame: 1 year

    Patient Global Impressions Scale - Improvement score (measurements of QoL) (PGI-I). Every question is scored from 1-7 (highest worst)

Study contacts

Contact information is provided by the study sponsor or research team.

Bo Biering-Soerensen, MD

CONTACT

[email protected]

40432773

Nikolaj la Cour Karottki, MD

CONTACT

[email protected]

40432773

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Odense University Hospital

Registry information

Official study title

PD-DigiCare: Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes - a Multicentre Randomized Controlled Trial.

Acronym: PD-DigiCare

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 29, 2024
Registry last updated
Jun 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.